Mr. Hai Zhao, Chairman of OliBio, Invited to Speak at the 2024 China Summit on Gene and Cell Therapy (CSGCT)

On June 14-15, 2024, the 2024 China Summit on Gene and Cell Therapy (CSGCT) was grandly held in Suzhou.

Mr. Zhao Hai, Chairman of Olipharma, was invited to participate in the roundtable forum on the application of small nucleic acids. He engaged in in-depth discussions and shared insights with industry experts and scholars on the prospects of disease areas for small nucleic acid drug applications and corporate pipeline layout strategies.

Mr. Zhao Hai pointed out that the pipeline layouts of leading global companies in the small nucleic acid field have certain differentiation, including Alnylam's focus on liver targeting, brain neurons, and lung diseases, as well as Arrowhead’s emphasis on cardiovascular, pulmonary, and hepatic disease areas. Meanwhile, clinical pipelines and R&D projects of small nucleic acid companies in China also demonstrate their own innovations.

Currently, the CMC projects executed by Olipharma are customized based on specific customer needs, allowing some of the customers' innovative ideas to be transformed into creative solutions and delivery plans under the execution of Olipharma's experienced team. In addition, Olipharma has successfully developed challenging processes and solutions such as multi-step conjugation of nucleic acid drugs and solid-phase synthesis of long-chain nucleic acids, which can empower various innovative forms of nucleic acid drugs and assist partners in their R&D innovation.

Finally, we look forward to China-produced small nucleic acid pharmaceutical companies achieving breakthroughs in a vast innovative space, leading the development of related technologies, and continuously introducing new products!

Wan Jin Qiao, CEO of Chengdu Xianyan Biotechnology

Xuefeng Zhang Co-Founder/COO of Ji Jin Bio

Tian Weiwei, Vice General Manager of Sirnaomics

Hai Zhao, Founder of Olipharma

Suzhou Olipharma Technology Co., Ltd. is a professional pharmaceutical nucleic acid CRDMO company that provides customers with "one-stop" services ranging from nucleic acid drug discovery, laboratory R&D, process and analytical development, CMC services, API production, to drug registration. The technical team of Olipharma comes from one of the earliest groups in China that began developing nucleic acid drug manufacturing processes and conducting CMC research, possessing extensive experience in project development and product registration. Currently, the company has established four industry-leading core technology platforms: nucleic acid solid-phase synthesis, chemical modification and conjugation, process development and analysis, and CMC pharmaceutical research. It has also engaged in in-depth collaborations with multiple pharmaceutical companies and biotechnology firms both within and outside China.

In 2023, the company's 3,000-square-meter GMP-compliant pilot platform officially began offering services, focusing on helping customers address key challenges such as process scale-up and CMC pharmaceutical research for small nucleic acid drugs. The company will continue to provide compliant, high-quality, reliable, and efficient services to help customers enhance R&D efficiency, accelerate product registration and market entry, and jointly support the entire process of small nucleic acid drug development from preclinical to commercial production.

Email: order@olipharma.com

Official Website: www.olipharma.com

Production Base: Building C3, Phase I Factory, No. 999 Yishanhu Road, Guoxiang, Wuzhong District, Suzhou City, Jiangsu Province